Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Natural Killer Cells and Bortezomib to Treat Cancer
This study is currently recruiting participants.
Verified April 2013
by National Institutes of Health Clinical Center (CC)
Study NCT00720785 Information provided by National Institutes of Health Clinical Center (CC)
First Received on July 22, 2008. Last Updated on April 17, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lung or Prostatic Neoplasms
Colorectal or Kidney Neoplasms
Pancreatic Neoplasms
Melanoma
CLL
Additional conditions recognized in this trial
Kidney Neoplasms
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Neoplasms
Prostatic Neoplasms
More general conditions related to this trial
Bone Marrow Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Kidney Diseases
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pancreatic Diseases
Prostatic Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Additional drug interventions recognized in this trial
Bortezomib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)
Back to top of Main Content
